logo
Plus   Neg
Share
Email

Accenture Chairman & CEO Pierre Nanterme Steps Down; Names Rowland Interim CEO

Accenture (ACN) said that effective immediately, Chairman and chief executive officer Pierre Nanterme has stepped down for health reasons.

The company appointed David Rowland, who has been Accenture's chief financial officer, to become interim chief executive officer, and to the board as a director of Accenture; and named lead independent director Marge Magner as the company's non-executive chair of the board.

The company also appointed KC McClure, who currently leads Accenture's finance operations, as chief financial officer. Nanterme will continue at Accenture as advisor to the chief executive office.

Rowland has served as Accenture's chief financial officer since July 2013. Throughout his 35-year career with the company, he has held significant leadership roles and played a lead role shaping Accenture's growth strategy. Rowland is a longstanding member of Accenture's Global Management Committee and has served on the board and as Audit Committee chair for Avanade, a joint venture of Accenture and Microsoft. Prior to being named CFO, Rowland served for more than six years as Accenture's senior vice president of Finance and chaired Accenture's Operations Council.

McClure brings to her new role as chief financial officer 30 years of experience with the company. Most recently, she led finance operations across the entirety of Accenture's business. McClure has also led investor relations and was finance director for two of Accenture's operating groups. In her new role, McClure will join Accenture's Global Management Committee.

Accenture confirmed that there is no change to the business outlook for the second quarter and full fiscal year 2019 that the company provided as part of its first quarter fiscal 2019 earnings announcement on December 20, 2018.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018. Shares of BMW Group declined around 5 percent in German trading after the auto giant reported Wednesday weak profit in its fiscal year 2018, despite a 0.1 percent growth in Automotive revenues with higher deliveries. Looking ahead for fiscal 2019, the company expects Group profit before tax will be well below the previous year's level. BMW said it is confident of volume growth in Automotive unit.
Follow RTT